Qianqian Xue
Research Subjects
Qianqian Xue has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Weibing Miao
Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
2 shared publications - Bin Qiu
Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China
1 shared publication F Zhang
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication- Guang-Yu Bai
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication P Song
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication- Shugeng Gao
Thoracic Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- 12 August 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (12) , 1079-1081
68Ga-FAPI and 18F-FDG PET/CT Images of a Patient With Rosai-Dorfman Disease With Liver Involvement
Rosai-Dorfman disease is a rare non-Langerhans cell histiocytosis that is histopathologically characterized by the accumulation of CD68-positive and S100-positive histiocytes. The pathological changes are mostly discovered in lymph nodes. We report a case of Rosai-Dorfman disease with liver and bone marrow involvement. In this case, 18F-FDG PET/CT revealed FDG avidity in multiple lymph nodes, liver, and bone marrow. 68Ga-FAPI PET/CT showed higher uptake of 68Ga-FAPI than that of 18F-FDG in the same lesions. The findings of 68Ga-FAPI PET/CT in this patient highlighted the potential value of 68Ga-FAPI for staging in Rosai-Dorfman disease.
- 12 August 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (12) , 1079-1081
68Ga-FAPI and 18F-FDG PET/CT Images of a Patient With Rosai-Dorfman Disease With Liver Involvement
Rosai-Dorfman disease is a rare non-Langerhans cell histiocytosis that is histopathologically characterized by the accumulation of CD68-positive and S100-positive histiocytes. The pathological changes are mostly discovered in lymph nodes. We report a case of Rosai-Dorfman disease with liver and bone marrow involvement. In this case, 18F-FDG PET/CT revealed FDG avidity in multiple lymph nodes, liver, and bone marrow. 68Ga-FAPI PET/CT showed higher uptake of 68Ga-FAPI than that of 18F-FDG in the same lesions. The findings of 68Ga-FAPI PET/CT in this patient highlighted the potential value of 68Ga-FAPI for staging in Rosai-Dorfman disease.
- 23 July 2021
- Published by Wolters Kluwer Health
- Vol. 43 (7) , 743-750
[Progress in diagnosis and treatment of lung adenocarcinomas imaging manifesting as radiological part-solid nodule].
The incidence and mortality of lung cancer ranked the first in China. China had 787, 000 new cases of lung cancer in 2015, and a majority of these patients with advanced lung cancer. With the development and popularization of high-resolution computed tomography, more and more early-stage lung adenocarcinomas are found in screening. The imaging finding of early-stage lung adenocarcinomas often manifests as part solid nodule (PSN) containing ground glass opacity (GGO). Although the imaging manifestation of the nodules can't accurately predict the pathologic type of nodules, the parts of solid nodule and GGO still have some pathologic indications, and the prognostic evaluation effect of the maximum diameter of PSN is superior to that of the whole nodule. With the development of the molecular radiography and molecular pathology, the relationship of imaging manifestation of the PSN and metastasis were focused on. Some PSNs with special nature are more active and rapidly progressed than the pure GGOs. While compared to the pure solid nodules, the aggressiveness of PSNs are insufficient, with lower metastatic rates of lymph node and better prognoses. Currently, international acknowledge recommends to take active intervention measure for PSNs which are highly suspected to be malignant. We focus on the diagnosis and treatment of PSNs, systemically depict their staging, follow-up, surgical treatment, gene detection and immunotherapy.
- 23 July 2021
- Published by Wolters Kluwer Health
- Vol. 43 (7) , 743-750
[Progress in diagnosis and treatment of lung adenocarcinomas imaging manifesting as radiological part-solid nodule].
The incidence and mortality of lung cancer ranked the first in China. China had 787, 000 new cases of lung cancer in 2015, and a majority of these patients with advanced lung cancer. With the development and popularization of high-resolution computed tomography, more and more early-stage lung adenocarcinomas are found in screening. The imaging finding of early-stage lung adenocarcinomas often manifests as part solid nodule (PSN) containing ground glass opacity (GGO). Although the imaging manifestation of the nodules can't accurately predict the pathologic type of nodules, the parts of solid nodule and GGO still have some pathologic indications, and the prognostic evaluation effect of the maximum diameter of PSN is superior to that of the whole nodule. With the development of the molecular radiography and molecular pathology, the relationship of imaging manifestation of the PSN and metastasis were focused on. Some PSNs with special nature are more active and rapidly progressed than the pure GGOs. While compared to the pure solid nodules, the aggressiveness of PSNs are insufficient, with lower metastatic rates of lymph node and better prognoses. Currently, international acknowledge recommends to take active intervention measure for PSNs which are highly suspected to be malignant. We focus on the diagnosis and treatment of PSNs, systemically depict their staging, follow-up, surgical treatment, gene detection and immunotherapy.
- 1 August 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (8) , 608-609
Spontaneous Recovery of Rosai-Dorfman Disease on FDG PET/CT
Rosai-Dorfman disease is a rare systemic proliferative disorder of histiocytes, which mainly manifests as lymphadenopathy but also often involves extranodal tissues. Rosai-Dorfman disease was often self-limited. We hereby report a case of Rosai-Dorfman disease involving both the lymph nodes and the lungs, which was spontaneously resolved on FDG PET/CT.
- 1 August 2017
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (8) , 608-609
Spontaneous Recovery of Rosai-Dorfman Disease on FDG PET/CT
Rosai-Dorfman disease is a rare systemic proliferative disorder of histiocytes, which mainly manifests as lymphadenopathy but also often involves extranodal tissues. Rosai-Dorfman disease was often self-limited. We hereby report a case of Rosai-Dorfman disease involving both the lymph nodes and the lungs, which was spontaneously resolved on FDG PET/CT.